Most recomposition research in the literature studies peptides in isolation. That’s useful for establishing mechanism, but it misses what observational researchers are increasingly documenting: GLP-1 class peptides and growth hormone secretagogues appear to work through complementary, non-overlapping pathways that address both sides of the recomposition equation simultaneously.
The recomposition problem with single-agent approaches
GLP-1 agonists are highly effective at reducing body mass. They are less effective at preserving the composition of that mass. Research subjects in GLP-1 trials consistently show meaningful lean mass loss alongside fat loss — in some studies, 25–40% of total weight lost is lean tissue. For researchers studying long-term metabolic outcomes, this is a significant confounding variable.
Growth hormone secretagogues — Ipamorelin, CJC-1295, Sermorelin — work through an entirely different axis. They don’t suppress appetite. They stimulate endogenous GH release, which drives IGF-1 production, nitrogen retention, and anabolic signaling. In a caloric deficit, this signal acts as a brake on lean tissue catabolism.
What researchers track
For researchers documenting recomposition protocols, the relevant markers span both pathways. On the GLP-1 side: fasting glucose, HbA1c, HOMA-IR, and of course body weight and composition scans (DEXA preferred over scale weight). On the GH side: IGF-1 is the primary proxy — taken in a fasted state, mid-morning, at least 3–4 weeks into a stable protocol. IGFBP-3 adds context but is less commonly tracked outside formal research settings.
Strength markers — grip strength, progressive resistance performance — provide a functional indicator of lean mass trajectory that doesn’t require imaging. Researchers observing subjects in resistance training contexts find these metrics more responsive to protocol changes than body composition scans at short intervals.
Protocol notes from the research community
Timing of secretagogue administration relative to food and sleep matters for research accuracy. GH is released in pulses, primarily overnight. Secretagogues administered 30–60 minutes before sleep, in a fasted state, show more consistent IGF-1 response in observational data than daytime administration with food present. Researchers measuring IGF-1 as a response marker should standardize draw conditions — same time of day, same fasted duration — across all measurement points.
The interaction between GLP-1 class compounds and GH axis activity is not well characterized in the formal literature but is an active area of observational interest. Some researchers report that the caloric deficit induced by GLP-1 agonists attenuates GH secretagogue response, possibly due to altered ghrelin dynamics. Adequate protein intake appears to be a moderating variable.
Research use only. All compounds discussed are for research purposes only. This content synthesizes published literature and observational data. It does not constitute medical advice or a treatment protocol.